Evaluating Cancer Drugs in Patients with Central Nervous System Metastases: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 1, 2021
July 3, 2021
cd630104-b6ee-4993-a2ff-85effca3e866
Related Documents
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry
Guidance DocumentDecember 19, 2018Center for Drug Evaluation and Research
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Guidance DocumentMay 26, 2023Center for Drug Evaluation and Research
Premenopausal Women with Breast Cancer: Developing Drugs for Treatment: Guidance for Industry
Guidance DocumentJune 17, 2021Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox